100 citations
,
July 2006 in “British Journal of Dermatology” This study found that intralesional triamcinolone acetonide injections using a needleless injector led to rapid hair regrowth in patients with limited alopecia areata, while lasting growth was rare in alopecia totalis.
65 citations
,
September 1999 in “The Journal of Dermatology” In this study, complete to excellent hair regrowth was observed in 63.3% of patients with extensive alopecia areata treated with biweekly dexamethasone pulses, although mild side effects were frequent.
132 citations
,
November 1998 in “Journal of the American Academy of Dermatology” This review evaluates the efficacy and safety of topical sensitizers in treating alopecia areata but reports no new clinical findings.
122 citations
,
November 1998 in “Archives of Dermatology” This study found that aromatherapy involving essential oils significantly improved symptoms of alopecia areata compared to carrier oils alone in a randomized controlled trial.
48 citations
,
July 1998 in “Pediatric Dermatology” This study found that pulsed doses of prednisolone led to excellent hair growth in 60% of young patients with widespread alopecia areata, with minimal side effects.
89 citations
,
October 1996 in “Dermatologic Clinics” This review discusses androgenetic alopecia and alopecia areata through a systems biology lens, emphasizing the role of multi-omics data integration to explore molecular mechanisms and potential therapeutic strategies, but offers no new clinical results.
117 citations
,
February 1996 in “International Journal of Dermatology” This study found that monthly oral prednisolone pulses of 300 mg were effective and safe for treating widespread alopecia areata, with 58.3% of patients achieving cosmetically acceptable hair growth.
105 citations
,
December 1995 in “British journal of dermatology/British journal of dermatology, Supplement” This retrospective study concluded that PUVA treatment is generally ineffective for alopecia areata, with low effective success rates for partialis, totalis, and universalis types.
47 citations
,
September 1995 in “British Journal of Dermatology” This review discusses the complication of vitiligo in patients undergoing diphencyprone sensitization therapy for alopecia universalis and reports no new clinical findings.
24 citations
,
November 1992 in “Archives of Dermatology” This study found that a 6-week taper of prednisone led to more than 25% hair regrowth in 30% to 47% of alopecia areata patients, and applying 2% topical minoxidil helped maintain this growth.
84 citations
,
August 1991 in “British Journal of Dermatology” This study found that 67% of children treated with diphencyprone for alopecia areata or alopecia totalis regrew scalp hair, with 33% achieving complete regrowth.
164 citations
,
November 1989 in “Clinical and Experimental Dermatology” This retrospective study found that juvenile alopecia areata is more severe and has a worse prognosis than maturity-onset alopecia areata.
36 citations
,
March 1989 in “Cleveland Clinic Journal of Medicine” 3% topical minoxidil effectively treats extensive alopecia areata.
101 citations
,
March 1987 in “Journal of The American Academy of Dermatology” Minoxidil solution helps hair regrowth in alopecia areata, with 5% being more effective.
104 citations
,
March 1987 in “Journal of The American Academy of Dermatology” Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.
63 citations
,
April 1985 in “Journal of the American Academy of Dermatology” This study observed that topical PUVA treatment led to excellent or good hair regrowth in 45.4% of patients with alopecia areata, though many experienced relapse after treatment stopped.
80 citations
,
October 1983 in “BMJ” This study found that 1% topical minoxidil induced significant hair regrowth in patients with alopecia areata, though it was less effective for those with extensive hair loss such as alopecia totalis and universalis.
75 citations
,
September 1971 in “British Journal of Dermatology” This study found that both intralesional triamcinolone acetonide and triamcinolone hexacetonide promote continuous hair growth in alopecia areata, with effects lasting at least 9 months after a single injection.